RLAY News and Press, Relay Therapeutics Inc.

2024-06-24 14:02:01 ET Summary Today, we take a look at Relay Therapeutics, Inc., which is focused on developing small molecule drug candidates for oncology and genetic diseases using its proprietary Dynamo Platform. The company believes this platform could significantly improve t...

2024-06-14 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay T...

2024-06-05 17:17:18 ET More on Pfizer, Relay Therapeutics Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) The Prognosis For Pfizer Relay Therapeutics upgraded by Barclays ahead of data readout ...

CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collabor...

2024-06-02 16:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-23 18:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that the company will host a N...

2024-05-10 16:30:03 ET Oppenheimer analyst issues MARKET OUTPERFORM recommendation for RLAY on May 10, 2024 02:00PM ET. The previous analyst recommendation was Market Outperform. RLAY was trading at $6.425 at issue of the analyst recommendation. The overall analyst conse...

2024-05-10 11:13:46 ET More on Relay Therapeutics Relay Therapeutics: Platform More Important Than Programs Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag Relay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09M ...